CINCINNATI, OH, July 10, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today it has launched its new affiliate network for ToConceive through W4 Performance Ad Market.
“W4 is excited by the potential of ToConceive and is looking forward to growing an outstanding affiliate network for Callitas,” said Abby Whitridge, COO of W4.
“We’re excited about introducing our affiliate network to customers and giving millions of people exclusive offerings,” said James Thompson, President and CEO. “The network will also allow us to incentivize influencers, thought leaders and bloggers to partner with our current and new products.”
Callitas, which focuses on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs, plans to include future products in the network along with ToConceive.
“Thanks to our affiliate network, we’ll significantly expand our reach for ToConceive,” said Joshua Maurice, Director of Sales and Marketing. “More couples will be exposed to our exciting product to help them improve their chances of having a child.”
W4’s network includes a variety of channels from email and newsletters to social media to blogs and websites. Unlike traditional advertising methods, using an affiliate network like W4’s allows Callitas to set its goals, choose its channels, and only pay for measurable results.
About W4: W4 operates an online advertising marketplace at w4.com that provides result-based advertising solutions to advertisers which include clients like Groupon and Netflix, and traffic monetization solutions for its publishing partners in social media, search, display, subscriber email and other channels. More information can be found at www.w4.com.
About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.
James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131
Investor Relations – Kevin McGrath, Managing Director
Phone: +1 (646) 418-7002
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.